Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation.


Journal Article

PURPOSE: Radiation therapy has recently emerged as a pivotal modality in the management of completely resected, high-risk gastric cancer. The recently published results of the Intergroup 0116 Gastric Surgical Adjuvant Trial randomized high-risk (T3,4 and/or node positive), completely resected gastric or gastroesophageal adenocarcinomas to receive either observation alone or radiochemotherapy after complete resection. Radiochemotherapy produced significant improvements in relapse-free (p < 0.0001) and overall survival (p = 0.01). Radiation oncologists must now clearly comprehend the principles governing the rationale supporting this therapy to apply it to those afflicted with this disease. This paper represents a consensus report reviewing data supporting radiotherapy, important clinical and anatomic issues related to radiotherapy, and details of the practical application of radiation therapy to commonly occurring clinical presentations. Supportive therapy during and after radiochemotherapy is also discussed.

Full Text

Duke Authors

Cited Authors

  • Smalley, SR; Gunderson, L; Tepper, J; Martenson, JA; Minsky, B; Willett, C; Rich, T

Published Date

  • February 1, 2002

Published In

Volume / Issue

  • 52 / 2

Start / End Page

  • 283 - 293

PubMed ID

  • 11872272

Pubmed Central ID

  • 11872272

International Standard Serial Number (ISSN)

  • 0360-3016

Digital Object Identifier (DOI)

  • 10.1016/s0360-3016(01)02646-3


  • eng

Conference Location

  • United States